STOCK TITAN

Zivo Bioscience Inc - ZIVO STOCK NEWS

Welcome to our dedicated page for Zivo Bioscience news (Ticker: ZIVO), a resource for investors and traders seeking the latest updates and insights on Zivo Bioscience stock.

Zivo Bioscience, Inc. (NASDAQ: ZIVO) is a biotechnology innovator focused on developing natural bioactive compounds derived from proprietary algal strains. This page serves as the definitive source for all official company announcements, research milestones, and strategic developments.

Investors and industry stakeholders will find timely updates including financial results, partnership agreements, regulatory filings, and scientific advancements. Our curated news feed provides essential insights into ZIVO's progress in nutraceutical research and biotech applications.

The page organizes content by key categories: quarterly earnings disclosures, product development breakthroughs, intellectual property updates, and corporate governance matters. Each news item is presented with clear context to help users assess material developments.

Bookmark this resource for streamlined tracking of Zivo Bioscience's advancements in algal-based biotechnology. Check regularly for verified updates directly from company filings and authorized communications.

Rhea-AI Summary

ZIVO Bioscience (OTCQB: ZIVO) announces a second collaborative study with the University of Delaware to explore applications of its proprietary algal-derived ingredients in fighting Low Pathogenicity Avian Influenza (LPAI) virus in poultry. The announcement follows their previous successful study that showed significant reduction in viral shedding and delayed disease transmission in treated birds.

The new study aims to optimize formulations and treatment protocols for real-world poultry production environments. Several global animal health companies have expressed interest in ZIVO's non-antibiotic solutions, following positive results from both avian influenza and coccidiosis studies. The company's approach focuses on developing sustainable, cost-effective alternatives to traditional treatments using their proprietary algal cultures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
none
-
Rhea-AI Summary

ZIVO Bioscience (OTCQB: ZIVO), a biotech/agtech R&D company focused on developing therapeutic, medicinal, and nutritional products from proprietary algal cultures, has announced its participation in The Microcap Conference 2025. The event will take place from January 28-30, 2025, in Atlantic City, New Jersey.

The company's management team will deliver a corporate presentation on Thursday, January 30, 2025, at 2:30 PM Eastern Time at Studio 1, Borgata Hotel Casino & Spa. During the conference, management will engage in one-on-one meetings with institutional and individual investors to discuss recent developments, growth strategy, and investment opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
conferences
-
Rhea-AI Summary

Zivo Bioscience has reported progress in licensing its coccidiosis treatment for broiler chickens. Following positive results from a 42-day study announced in August 2024, Zivo is discussing an exclusive license with major global animal health companies. Due diligence processes are underway, including technical evaluations, patent reviews, and business case assessments. Formal negotiations are expected to start in January 2025, with an agreement anticipated in Q1 2025. Zivo aims for a deal with upfront payment, milestone payments, and royalties. CEO John B. Payne highlighted the product's potential to enhance ionophores and vaccines. Additionally, Zivo is advancing its product targeting Low Pathogenicity Avian Influenza (LPAI) virus in poultry, planning further studies at the University of Delaware to optimize dosage and formulation. Payne noted the active ingredients' effectiveness against both parasitic and viral diseases, offering commercial opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.32%
Tags
none
Rhea-AI Summary

ZIVO Bioscience (OTCQB: ZIVO) reports positive results from a University of Delaware study evaluating its proprietary active ingredients against Low Pathogenicity Avian Influenza (LPAI) in poultry. The two-part study showed statistically significant findings including reduced viral shedding in infected birds and delayed LPAI transmission when healthy birds were exposed to infected ones.

The study demonstrated that birds receiving ZIVO's ingredients experienced an early significant decrease in viral titers compared to untreated controls. Different product configurations showed varying effectiveness, with some better at lowering viral titer and others at slowing spread, suggesting potential for comprehensive protection through optimal product configuration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
none
-
Rhea-AI Summary

ZIVO Bioscience, Inc. (OTCQB: ZIVO) reports favorable results from a 42-day study of its coccidiosis treatment in broiler chickens. The study, conducted with a major global animal health company, showed that ZIVO's non-antibiotic, immune-modulating product significantly improved growth performance and reduced clinical signs of disease when used in combination with existing treatments. Chickens treated with ZIVO's product alongside an ionophore or vaccination achieved feed conversion ratios comparable to healthy, uninfected birds. This demonstrates the product's potential to enhance current treatment options and its standalone treatment capabilities for coccidiosis, a major challenge in poultry production.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
none
-
Rhea-AI Summary

ZIVO Bioscience (NASDAQ: ZIVO) announced the start of a 42-day confirmatory study in partnership with a major global animal health company to validate its non-antibiotic coccidiosis treatment for broiler chickens. This study, building on previous positive results, aims to ensure the product's effectiveness under commercial poultry production conditions. The study compares ZIVO's product with traditional ionophore-based treatments and explores combinations with coccidiosis vaccines. The goal is to provide a sustainable, antibiotic-free solution to address the $10 billion annual loss in the poultry industry due to coccidiosis. The results are expected by September.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
none
Rhea-AI Summary
Zivo Bioscience, Inc. announces positive findings from a 42-day coccidiosis challenge study, demonstrating the impact of its product on broiler production. The product reduces intestinal damage caused by the Eimeria parasite, leading to improved feed utilization and a better Feed Conversion Ratio (FCR), which drives profitability. These results position ZIVO's product as a potential game-changer in the poultry industry, offering improved outcomes at cost parity or better.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
none
-
Rhea-AI Summary
Zivo Bioscience, Inc. (ZIVO) has successfully uplisted its common stock from the OTC Pink Market to the OTCQB Venture Market, under the ticker symbol 'ZIVO'. This move is aimed at enhancing visibility, improving market access, and increasing liquidity for shareholders. The OTCQB listing requires compliance with higher standards, financial reporting with the SEC, minimum bid price test, audited financials, and company verification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
none
-
Rhea-AI Summary
Zivo Bioscience, Inc. announces positive results from a 42-day coccidiosis challenge study, demonstrating the effectiveness of its immune-modulating treatment for broiler chickens. The study showed that the product candidate is comparable to a market-leading anticoccidial product containing antibiotics and chemicals. Zivo will pursue a partnership with a global animal health company for commercializing its coccidiosis product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.74%
Tags
none
Rhea-AI Summary
Zivo Bioscience, Inc. is conducting a 42-day study to validate the efficacy of its immune-modulating treatment for coccidiosis in broiler chickens. The study aims to confirm the positive effects of Zivo's non-antibiotic alternative, including reduced mortality and improved bird growth rates. The study will also analyze secondary benefits such as protection of intestinal tissue and reduction of pathogenic bacteria.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
none
Zivo Bioscience Inc

OTC:ZIVO

ZIVO Rankings

ZIVO Stock Data

66.54M
1.86M
50.32%
0.07%
2.04%
Biotechnology
Healthcare
Link
United States
Bloomfield Hills